

## **HTAi Interest Group News**

### **Research Projects**

The Steering Committee of the HTAi Interest Group on Assessment of Vaccination Programmes has agreed to undertake two research projects to evaluate how vaccination programmes are assessed internationally. The methodology for the work is outlined in the first attachment.

### **Presentations at HTAi 2017 Rome Conference**

Saturday 17 June, Afternoon. Pre-conference workshop to discuss the emerging results of research Project 1 – comparing how vaccines are assessed in different countries. See the abstract in the second attachment. Please do register to join this important event  
Monday 19 June, 11.30am-1pm: Panel discussion on Project 2, discussing the duplication of assessment between HTA bodies and National Immunization Technology Assessment Groups. See the abstract in the third attachment.

### **Annual General Meeting**

Our AGM will be held at the HTAi conference on Monday 19 June from 1-2.30pm. Please prioritise this in your conference diaries so that we can hear your views on the work of the Interest Group and future activities.

### **Future bulletins – only sent to HTAi members**

Please note that HTAi is reviewing its email lists and anyone who is not an HTAi member will be removed from this email list. So please ensure you are signed up as an HTAi member if you want to remain a member of this Interest Group. <https://www.xcdsystem.com/htai/member/>

## **Policy News**

### **Launch of the EU Joint Action on Vaccination**

The European Commission launched the EU Joint Action on Vaccination under the 2017 Health Work Programme published on 26th January 2017. This Joint Action is a three-year engagement that will be co-funded by the EU Commission and Member States, with funding of 3 Million Euros, at EU level. It acts under the objective 'Protecting Union citizens from serious cross-border health threats' with the aim to establish sustainable cooperation of Member States authorities dealing with vaccination and to provide a framework to practically address further issues related to vaccination and preparedness.

This EU Joint Action represents a real opportunity to address common challenges faced by the EU Member States that were highlighted in the *Council Conclusions on vaccinations as an effective tool in public health in December 2014*. This becomes even more relevant against a background of increasing vaccine preventable disease outbreaks across Europe and with the ageing of the population, especially when paired with chronic health conditions (cardiovascular disease, chronic respiratory diseases, diabetes mellitus etc.). A multistakeholder workshop is being organized by the EU Commission to kick-off and define the working priorities, end of April 2017. This unprecedented pan-European action demonstrates that prevention through immunisation, is a public health priority which deserves strengthened programmes' assessment and management across Europe.

See : [https://ec.europa.eu/health/programme/events/adoption\\_workplan\\_2017\\_en](https://ec.europa.eu/health/programme/events/adoption_workplan_2017_en)

More info: [act](#), [annexes](#) and the [summary](#)

## FRANCE

The Haute Autorite Sante (HAS) will take over the leadership for vaccination policy and issuing vaccination recommendations. These missions were previously carried out by the Technical Committee on Immunizations of the High Council of Public Health (HCSP). To fulfill this mission, HAS will rely on epidemiological data, studies on the efficacy and tolerance of vaccination, at individual and collective levels, and medico-economic studies. A specialized committee on vaccination technical commission (CTV) will be set up at HAS.

The HAS Technical Commission for Vaccination (CTV) will be in charge of the evaluation of vaccines and the development of vaccination strategies. The main tasks of CTV will be to:

- Provide expertise in vaccines and vaccinations;
- Ensure scientific monitoring of vaccine developments and prospects;
- Propose a vaccination strategy based on epidemiological data and the benefit-risk balance at the individual and collective levels, as well as the cost-effectiveness of the measures envisaged;
- Propose adaptations with regard to vaccine recommendations for updating the vaccination schedule.

The CTV will work closely with the HAS committees already involved in the evaluation of health products: the Transparency Commission (CT), for the inclusion of vaccines on the list of reimbursable medicines, and The Committee on Economic and Public Health Evaluation (CEESP), when the vaccine is likely to have a significant impact on health insurance expenditure.

[http://www.has-sante.fr/portail/jcms/c\\_2742985/en/vaccination](http://www.has-sante.fr/portail/jcms/c_2742985/en/vaccination)